Discover

NTLA
Intellia Therapeutics, Inc.
11.94
1 x 11.45
1 x 12.07
bid
ask
+
0.70
6.23%
100 @ 04:00 PM
11.99 +0.05 (0.42%)
Ytd32.81%
1y4.19%
11.47
day range
12.08
8.04
52 week range
27.98
Open11.98Prev Close11.24Low11.47High12.08Mkt Cap1.34B
Vol4.74MAvg Vol5.69MEPS-3.36P/E-3.55Forward P/E-8.25
Beta1.77Short Ratio7.30Inst. Own76.79%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg13.65200-d Avg13.011yr Est26.17

NTLA News

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
zacks.com
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration reven

Intellia Therapeutics Q2 Earnings Call Highlights
marketbeat.com
Intellia Therapeutics Q2 Earnings Call Highlights

Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
zacks.com
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
globenewswire.com
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages
defenseworld.net
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average reco

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
globenewswire.com
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial R

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
defenseworld.net
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA

Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASD

3 Promising Genomics Stocks to Add to Your Portfolio in 2026
zacks.com
3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid a

This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
benzinga.com
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha

benzinga.com
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain
benzinga.com
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome

benzinga.com
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
zacks.com
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progr

A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
fool.com
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destr

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a le

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
fool.com
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%

It might pull it off, provided several things fall right in place.

Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
benzinga.com
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
fool.com
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipel

Dow Extends Record Run as Fed Decision Looms
schaeffersresearch.com
Dow Extends Record Run as Fed Decision Looms

Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once aga

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a

This Stock Is Up 58% This Year. Is It too Late to Buy?
fool.com
This Stock Is Up 58% This Year. Is It too Late to Buy?

There could be additional catalysts for this drugmaker over the next year.

NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
zacks.com
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up

Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
zacks.com
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga.com
Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For February 26, 2026
benzinga.com
Earnings Scheduled For February 26, 2026

Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday
benzinga.com
Walt Disney To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday

benzinga.com
Earnings Scheduled For August 7, 2025

benzinga.com
Earnings Scheduled For May 8, 2025

benzinga.com
Earnings Scheduled For February 27, 2025

benzinga.com
Earnings Scheduled For February 22, 2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings

benzinga.com
Earnings Scheduled For November 9, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

benzinga.com
Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday

benzinga.com
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018

Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018